Culture of Caco2 cells Sample Clauses

Culture of Caco2 cells. Acute exposure (24h) for ToF XXXX For ToF-XXXX analysis, cells were cultivated on wafers (polished size up) in 24 xxxxx plates. Caco2 cells were seeded at a density of 20 000 cells/cm². Culture medium was changed three times a week. Cells were differentiated during 25–27 days post-seeding. NPs (NM103 and NM104 provided by the JRC) were dispersed in a mixture of water/BSA 0.05 % (p/v) according to the NANoREG Guidance Document. Differentiated Caco2 were incubated with 3 concentrations of each NP (0.75, 3.13 and 12.5 µg/cm2) (2 replicates per concentration) for 24h. After exposure the cells were rinsed twice with NH4CO3 (144 mM), collected gently, fast-frozen in liquid nitrogen and freeze-dried for the ToF-XXXX analysis. Repeated exposure with or without a recovery period Cells were seeded at 20.000 cells/cm². Culture medium was changed three times a week. Cells were differentiated during 21 days post-seeding. Cells were repeatedly exposed to NM103 or NM104: medium was changed every two or three days and replaced by new medium supplemented with fresh NP solution prepared according to the NANoREG Guidance Document. Cells were exposed for 1 day, 1 week or 2 weeks. In some cases, exposure was followed by a recovery period of up to 1 week as described below. The concentrations were: From 6.5 to 50 µg/cm2 for 24h exposure From 3 to 12.5 µg/cm2 for 1 and 2 weeks exposure. Concentrations tested: - 50 and 12.5 µg/cm2 for 24h recovery - 12.5 and 3 µg/cm2 for longer times Medium changed every 2 or 3 days Treament phase with NM Recovery phase without NM Sampling Treatment schedule for acute and repeated exposure of differentiated Caco2 cells to NM103 and NM104 followed or not by a recovery period (up to 1 week). After exposure, the cells were harvested for estimation of cytotoxicity (Neutral Red Uptake) and IL8 release. Immunostaining of toxicity markers linked with a TEM detection was performed for High Content Screening.
AutoNDA by SimpleDocs

Related to Culture of Caco2 cells

  • Vaccination and Inoculation (a) The Employer agrees to take all reasonable precautions, including in-service seminars, to limit the spread of infectious diseases among employees.

  • Culture e) History and past behavior;

  • Prosthetics Crowns and Bridges (Plan B) paying for 60% of the approved Schedule of Fees.

  • Rhytidectomy Scar revision, regardless of symptoms. • Sclerotherapy for spider veins. • Skin tag removal. • Subcutaneous injection of filling material. • Suction assisted Lipectomy. • Tattooing or tattoo removal except tattooing of the nipple/areola related to a mastectomy. • Treatment of vitiligo. • Standby services of an assistant surgeon or anesthesiologist. • Orthodontic services related to orthognathic surgery. • Cosmetic procedures when performed primarily: o to refine or reshape body structures or dental structures that are not functionally impaired; o to improve appearance or self-esteem; or o for other psychological, psychiatric or emotional reasons. • Drugs, biological products, hospital charges, pathology, radiology fees and charges for surgeons, assistant surgeons, attending physicians and any other incidental services, which are related to cosmetic surgery.

  • Influenza Vaccination The parties agree that influenza vaccinations may be beneficial for patients and employees. Upon a recommendation pertaining to a facility or a specifically designated area(s) thereof from the Medical Officer of Health or in compliance with applicable provincial legislation, the following rules will apply:

  • Hepatitis B Vaccine Where the Hospital identifies high risk areas where employees are exposed to Hepatitis B, the Hospital will provide, at no cost to the employees, a Hepatitis B vaccine.

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • Biological Samples If so specified in the Protocol, Institution and Principal Investigator may collect and provide to Sponsor or its designee Biological Samples (“Biological Samples”). 12.2.

  • Unbundled Channelization (Multiplexing) 5.7.1 To the extent NewPhone is purchasing DS1 or DS3 or STS-1 Dedicated Transport pursuant to this Agreement, Unbundled Channelization (UC) provides the optional multiplexing capability that will allow a DS1 (1.544 Mbps) or DS3 (44.736 Mbps) or STS-1 (51.84 Mbps) Network Elements to be multiplexed or channelized at a BellSouth central office. Channelization can be accomplished through the use of a multiplexer or a digital cross-connect system at the discretion of BellSouth. Once UC has been installed, NewPhone may request channel activation on a channelized facility and BellSouth shall connect the requested facilities via COCIs. The COCI must be compatible with the lower capacity facility and ordered with the lower capacity facility. This service is available as defined in NECA 4.

  • Clinical 2.1 Provides comprehensive evidence based nursing care to patients including assessment, intervention and evaluation.

Time is Money Join Law Insider Premium to draft better contracts faster.